Gyre Therapeutics, Inc.
GYRE
$6.13
$0.081.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -404.41% | -147.73% | 716.74% | -83.62% | 2,825.25% |
| Total Depreciation and Amortization | -3.31% | 7.09% | 1.25% | 19.81% | 7.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.43% | 80.26% | 92.23% | -34.58% | 245.12% |
| Change in Net Operating Assets | 196.88% | -300.37% | -410.50% | 91.54% | -47.47% |
| Cash from Operations | 156.53% | -220.30% | 123.95% | 1,718.60% | 95.32% |
| Capital Expenditure | -23.61% | 78.44% | -160.94% | -109.84% | -287.69% |
| Sale of Property, Plant, and Equipment | -45.45% | -- | -100.00% | 1,700.00% | -99.28% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -245.53% | 442.14% | 79.35% | -234.29% | 194.61% |
| Cash from Investing | -265.31% | 248.20% | 59.01% | -254.65% | 198.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -93.40% | 536.00% | -99.79% | 1,540.41% | 10.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | 118.74% | -1,289.26% | 67.03% |
| Cash from Financing | -93.40% | -12.88% | -98.37% | 1,563.02% | 39.42% |
| Foreign Exchange rate Adjustments | 124.41% | 8.55% | 138.78% | -2.00% | 119.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.94% | -185.20% | -81.76% | 563.55% | 179.74% |